TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20066873

Group type: EXPERIMENTAL
Intervention: Digital multimedia instruction (DVD)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 2
Study: 17605534

Group type: EXPERIMENTAL
Intervention: Realistic violent video game
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fantasy violent video game
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 112
Study: 14988623

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 11805412

Group type: EXPERIMENTAL
Intervention: Patients with interstitial cystitis (IC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control patients (non-IC)
Number of subjects: 30
Study: 9517646

Group type: EXPERIMENTAL
Intervention: 4-day low dose triple therapy (LAT group): lansoprazole 30 mg b.i.d. on days 1-4, azithromycin 500 mg u.i.d. on days 2-4, tinidazole 2000 mg u.i.d. on day 3
Number of subjects: 160

Group type: COMPARATOR
Intervention: 1-week triple therapy (OCT group): omeprazole 20 mg u.i.d., clarithromycin 250 mg b.i.d., tinidazole 500 mg b.i.d.
Number of subjects: 160
Study: 7922791

Group type: EXPERIMENTAL
Intervention: Unilateral strength training at 80% one repetition maximum for 1 year
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Detraining for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study: 3132244

Group type: EXPERIMENTAL
Intervention: Combined oestrogen and progestogen (continuous supplementation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined oestrogen and progestogen (sequential supplementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29191714

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulins
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 46
Study: 28176220

Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoids (ivGCs) - methylprednisolone with cumulative doses of 2.25, 4.98, 7.47 g
Number of subjects: 159
Study: 25456613

Group type: EXPERIMENTAL
Intervention: 5% CSPS dentifrice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo dentifrice (fluoride-only)
Number of subjects: 20
Study: 22622819

Group type: EXPERIMENTAL
Intervention: Supervised specific strength exercises for the neck and shoulder muscles for 20 minutes three times a week (n=282)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Reference group (n=255)
Number of subjects: 537
Study: 21934371

Group type: EXPERIMENTAL
Intervention: P group (random surface tilt perturbations, 3 times weekly for 3 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: P+EX group (random surface tilt perturbations + home vestibular rehabilitation exercises, 3 times weekly for 3 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: EX group (only vestibular rehabilitation exercises)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: P and P+EX groups (combined)
Number of subjects: 29
Study: 19145673

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen i.v. every 8h for 72h
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.5 g metamizole i.v. every 8h for 72h
Number of subjects: 60
Study: 16902267

Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: E-mail education
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 12042687

Group type: EXPERIMENTAL
Intervention: 10-week hospital-based angina management program (n = 75)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Routine care (n = 74)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Exercise therapy (n = 77)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 226
Study: 10505582

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study: 8562627

Group type: EXPERIMENTAL
Intervention: Dietary fat intake 12-24 months before diagnosis
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Percentage of calories as fat 12-24 months before diagnosis
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fat consumption 0-12 months prediagnostic interval
Number of subjects: 96
Study: 1940775

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg nightly in non-FH patients
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly in FH patients
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly in pooled patients (n = 224)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Lovastatin treatment
Number of subjects: 232
Study: 7007666

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 265
Study: 30142301

Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children (MATCH)
Number of subjects: 55
Study: 29072430

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model (HBM) conducted in five sessions with group discussions and training videos.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 92
Study: 24787312

Group type: EXPERIMENTAL
Intervention: Functioning pressure‐based sensor (FPS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nonfunctioning sensor (NFPS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No sensor (NS)
Number of subjects: 67
Study: 24264781

Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 123
Study: 21318412

Group type: EXPERIMENTAL
Intervention: BALANCE intervention (Motivational Interviewing plus feedback)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 228
Study: 19056606

Group type: EXPERIMENTAL
Intervention: L-carnitine 2 g once daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 18180889

Group type: EXPERIMENTAL
Intervention: Modified Wuzi Yanzong Granule (WYG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal control group (20 healthy subjects)
Number of subjects: 36
Study: 15359927

Group type: EXPERIMENTAL
Intervention: Postinjection transmission scan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Preinjection transmission scan
Number of subjects: 10
Study: 11486790

Group type: EXPERIMENTAL
Intervention: Orlistat (OLS) 120 mg three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10676140

Group type: EXPERIMENTAL
Intervention: Priming with the concept of neediness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming with the concept of safety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral concept activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjective rating task
Number of subjects: 0
Study: 9349964

Group type: EXPERIMENTAL
Intervention: Sequential treatment with 'Flowtron DVT' garments followed by Enoxaparin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Enoxaparin alone
Number of subjects: 44
Study: 8252746

Group type: EXPERIMENTAL
Intervention: Ethinyl oestradiol (20 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (1.25 mg Premarin)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg)
Number of subjects: 6
Study: 3545477

Group type: EXPERIMENTAL
Intervention: 0.5 mg metolazone
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 1.0 mg metolazone
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 2.0 mg metolazone
Number of subjects: 269

Group type: COMPARATOR
Intervention: 2.5 mg older metolazone
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: All metolazone groups
Number of subjects: 269
Study: 28939190

Group type: EXPERIMENTAL
Intervention: SARME without pterygomaxillary disjunction (PD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SARME with pterygomaxillary disjunction (PD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (SARME with PD)
Number of subjects: 24
Study: 27707550

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab (RBZ)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2.0 mg ranibizumab (RBZ)
Number of subjects: 152
Study: 24891437

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting high ferritin (400-600 µg/L)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting low ferritin (100-200 µg/L)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 626
Study: 22653940

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) workshop
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Low-Intensity Training (LIT) self-study
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Intervention groups (HIT and LIT)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: HIT and LIT with reimbursement
Number of subjects: 265
Study: 20308250

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) infusion at 125 mg kg(1) h(1) for 15 min and then at 25 mg kg(1) h(1) for 20 min before and throughout exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study: 18400273

Group type: EXPERIMENTAL
Intervention: Disposable transrectal needle guide
Number of subjects: 198

Group type: COMPARATOR
Intervention: Reusable needle guide
Number of subjects: 198
Study: 15807179

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12470771

Group type: EXPERIMENTAL
Intervention: Bradykinin (10 microg intradermal injection)
Number of subjects: 45
Study: 10635286

Group type: EXPERIMENTAL
Intervention: Test gum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unsweetened gum base
Number of subjects: 12

Group type: COMPARATOR
Intervention: No gum (control)
Number of subjects: 12
Study: 7489776

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (coffee-free period)
Number of subjects: 49
Study: 2024792

Group type: EXPERIMENTAL
Intervention: IV phenytoin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31144568

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (for patients with highly active disease)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (SC IFNB‐1a)
Number of subjects: 0
Study: 30045423

Group type: EXPERIMENTAL
Intervention: Milk fortified with beverage powder containing 7 mg isotopically labeled iron (57Fe/58Fe) as Fe4(P2O7)3 and equimolar proportions of ascorbic acid
Number of subjects: 25

Group type: COMPARATOR
Intervention: Milk fortified with energy, calcium and iron equivalent beverage powder
Number of subjects: 25
Study: 26995678

Group type: EXPERIMENTAL
Intervention: Multi-component, clinic-based HIV prevention intervention
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Control (comparison clinics)
Number of subjects: 3522
Study: 24615745

Group type: COMPARATOR
Intervention: AC (100 mg aspirin plus 75 mg clopidogrel)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACH (AC plus 20 mg famotidine twice-daily)
Number of subjects: 20
Study: 23073360

Group type: EXPERIMENTAL
Intervention: 30 ml of MgCl2 5% solution (equivalent to 382 mg of magnesium), daily for three months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20963535

Group type: EXPERIMENTAL
Intervention: Romiplostim (0.3, 1 and 10 μg/kg intravenous; 0.1, 0.3, 1, and 2 μg/kg subcutaneous)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Weekly dosing of Romiplostim
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dosing intervals ≥2 weeks of Romiplostim
Number of subjects: 32
Study: 18242155

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg i.v.
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 15936187

Group type: EXPERIMENTAL
Intervention: 5-min lockout interval
Number of subjects: 60

Group type: COMPARATOR
Intervention: 15-min lockout interval
Number of subjects: 60
Study: 14661614

Group type: EXPERIMENTAL
Intervention: PEA‐BP
Number of subjects: 93
Study: 11013539

Group type: EXPERIMENTAL
Intervention: Visual art programme (dialogues using pictures of works of art)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (dialogues about daily events)
Number of subjects: 40
Study: 8780818

Group type: EXPERIMENTAL
Intervention: Nevirapine plus ZDV (200 mg daily for 2 weeks followed by 200 mg twice daily for 26 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nevirapine plus ZDV
Number of subjects: 49
Study: 1600865

Group type: EXPERIMENTAL
Intervention: Levocarnitine propionyl
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 6365232

Group type: EXPERIMENTAL
Intervention: Niopam (iopamidol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conray (meglumine iothalamate)
Number of subjects: 20
Study: 30255454

Group type: EXPERIMENTAL
Intervention: Scalp cooling (CAP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Observation (NoCAP)
Number of subjects: 79
Study: 30268263

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in EEC group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in NEC group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Untreated control group (UC)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 86
Study: 26556733

Group type: EXPERIMENTAL
Intervention: Zoledronic acid infusion
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 79
Study: 24166063

Group type: EXPERIMENTAL
Intervention: 2 × ‐RDA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3 × ‐RDA
Number of subjects: 39

Group type: COMPARATOR
Intervention: RDA
Number of subjects: 39
Study: 22647480

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 0

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 0
Study: 21137649

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg IM
Number of subjects: 150

Group type: COMPARATOR
Intervention: Piroxicam 20 mg IM
Number of subjects: 150
Study: 17923601

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter plus clinical assessment
Number of subjects: 433

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 433
Study: 15704485

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 30 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebrolysin 10 ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (higher dosages)
Number of subjects: 0
Study: 12215163

Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn for 1 month each of 4 different brands over 4 months.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn by patients in CEAP class 4.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn by patients in CEAP class 5.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings worn by patients with primary disease.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Knee-high, open-toe, 30- to 40-mm Hg surgical compression stockings (all brands).
Number of subjects: 11
Study: 9468736

Group type: EXPERIMENTAL
Intervention: Cocaine cue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arousing cue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neutral cue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual cue modality
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Audio cue modality
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual cue modality
Number of subjects: 30
Study: 8548332

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV), n = 28
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo, n = 19
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 47
Study: 2222131

Group type: EXPERIMENTAL
Intervention: Fluoxetine for 10 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clomipramine for 10 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluoxetine after clomipramine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clomipramine after fluoxetine
Number of subjects: 32
Study: 857192

Group type: EXPERIMENTAL
Intervention: Sterectal (prednacinolone, lidocaine hydrochloride, ephedrine hydrochloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31868074

Group type: EXPERIMENTAL
Intervention: Direct Mapping of Grapheme (DMG) intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control condition (taught control)
Number of subjects: 71
Study: 31354146

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (VL)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 426
Study: 29179761

Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao acupuncture via intradermal needling
Number of subjects: 0
Study: 24373419

Group type: EXPERIMENTAL
Intervention: Immediate load post-extractive implant with subepithelial connective tissue graft (grafted group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Immediate load post-extractive implant without raising a flap (non-grafted group)
Number of subjects: 47
Study: 23880005

Group type: EXPERIMENTAL
Intervention: Pemetrexed (PEM) 500 mg/m² on day 1 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m² on days 1 and 8 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Number of subjects: 70
Study: 20805741

Group type: EXPERIMENTAL
Intervention: Concurrent radiation treatment
Number of subjects: 206

Group type: COMPARATOR
Intervention: Sequential radiation treatment
Number of subjects: 206
Study: 19486913

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17035647

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose, 5.5 mg per day)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose, 56.5 mg per day)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose, 1.0 mg per day)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 12854452

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best proven therapy
Number of subjects: 0
Study: 10588784

Group type: EXPERIMENTAL
Intervention: LAA flow velocity measured by TEE in patients with AF
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Anu(p) < 20 cm/s
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Clinical risk factors
Number of subjects: 721
Study: 8723575

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg twice weekly for 3 weeks)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 204
Study: 1914563

Group type: EXPERIMENTAL
Intervention: Catheters changed over a guidewire at three days and removed at seven days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Catheters left in situ for seven days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Catheters changed over a guidewire at three days
Number of subjects: 31
Study: 6341847

Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin G given within 60 minutes of birth
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Control group (no penicillin treatment)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin G
Number of subjects: 1187
Study: 29667488

Group type: EXPERIMENTAL
Intervention: Two-week intervention designed to increase relationship maintenance
Number of subjects: 60
Study: 28640389

Group type: EXPERIMENTAL
Intervention: PF plus 10 μg/m2 daily rhLTα‐Da
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PF plus 20 μg/m2 daily rhLTα‐Da
Number of subjects: 150

Group type: COMPARATOR
Intervention: PF alone
Number of subjects: 150
Study: 26974989

Group type: EXPERIMENTAL
Intervention: Intensive lowering of systolic blood pressure (goal < 120 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently recommended goal (< 140 mm Hg)
Number of subjects: 0
Study: 24411656

Group type: EXPERIMENTAL
Intervention: Educational intervention (40-min individualized education session using motivational techniques, reinforced by telephone 1 month later)
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Control group (usual in-hospital care)
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1944
Study: 21790794

Group type: EXPERIMENTAL
Intervention: Topical CPS (1% cantharidin, 5% podophyllotoxin, 30% salicylic acid)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 26
Study: 19258913

Group type: EXPERIMENTAL
Intervention: asmofilcon A contact lenses
Number of subjects: 60

Group type: COMPARATOR
Intervention: senofilcon A contact lenses
Number of subjects: 60
Study: 17580003

Group type: EXPERIMENTAL
Intervention: rTMS (n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: ECT (n = 22)
Number of subjects: 46
Study: 15065029

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg/dose 4 times daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11877070

Group type: EXPERIMENTAL
Intervention: Androgen combined with cyclosporin A (CsA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Androgen alone
Number of subjects: 0